DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Cancer Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Wencheng Zhang, M.D.) · zhangwencheng@tjmuch.com · 02223340123

Study leads

Wencheng Zhang, M.D.
Principal Investigator
Tianjin Cancer Hospital
Xiaofeng Duan, M.D.
Principal Investigator
Tianjin Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Oncolytic Virus in Esophageal Squamous Cell Carcinoma

Esophageal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Chengdu, China

A Beta-only IL-2 ImmunoTherapY Study

Advanced Solid Tumor · Unresectable Solid Tumor · Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

San Diego, United States · San Francisco, United States

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Advanced/Metastatic Solid Tumors · Colorectal Cancer · Gastric Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

La Jolla, United States · Los Angeles, United States

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

Esophageal Cancer

Abroad (travel likely)RecruitingPHASE2

Nanjing, China